Audalia Resources Finalizes $450,000 Placement to Propel Medcalf Project Towards Production

Key Points<\/h3>

• Company: Audalia Resources Limited (ASX:ACP)<\/li>
• Placement of $450,000 completed on 3 July 2026 to a single sophisticated investor<\/li>
• Issued 15,000,000 fully paid ordinary shares at $0.03 per share<\/li>
• Funds allocated to advancing the Medcalf project and general working capital<\/li>
• Company continues to explore all funding options for remaining regulatory approvals and permits<\/li>
• Investors should monitor updates on Medcalf project permitting milestones and future funding activities<\/li> <\/ul> <\/div>

  Audalia Resources Completes $450,000 Placement at $0.03 per Share<\/h2>

  On 3 July 2026, Audalia Resources Limited confirmed the successful completion of a placement raising $450,000 from a single sophisticated investor. The company issued 15 million fully paid ordinary shares at $0.03 each, with an Appendix 2A lodged on the same day to formalize the issuance.<\/p>

  This placement was initially disclosed in a company update dated 29 June 2026. The closing notice confirms the transaction’s completion and the formal issuance of shares. The $0.03 per share price reflects the current market conditions as Audalia progresses its Medcalf project through regulatory approvals towards production.<\/p>

  Allocation of Funds to Advance the Medcalf Project<\/h2>

  The raised capital will be utilized primarily to advance the Medcalf project towards production and to supplement general working capital. This dual allocation indicates Audalia’s effort to balance project development needs with ongoing operational expenses, a common challenge for ASX-listed early and development-stage resource companies.<\/p>

  The Medcalf project remains central to Audalia’s corporate strategy, with this funding intended to maintain development momentum. The company did not provide a detailed breakdown of the $450,000 allocation between project costs and working capital in this announcement.<\/p>

  Regulatory Approvals and Permitting Remain Key Milestones<\/h2>

  Audalia emphasized that it continues to evaluate all funding alternatives to secure the remaining regulatory approvals and permits necessary for the Medcalf project’s development. This indicates that permitting is ongoing and additional funding may be required beyond this placement to reach the next milestones.<\/p>

  For investors, the reference to outstanding regulatory approvals highlights the current stage of the Medcalf project. Permitting in the Australian resources sector often involves complex state and federal environmental, land-use, and operational approvals. The company did not specify which approvals remain outstanding or provide a timeline for their resolution in this update.<\/p>

  Placement to a Single Sophisticated Investor and Its Implications<\/h2>

  The placement was conducted with a single sophisticated investor, allowing Audalia to raise funds quickly without the disclosure requirements imposed on retail investors under Part 6D.2 of the Corporations Act 2001. This method is commonly used by smaller ASX-listed companies to expedite capital raising, especially when bridging funds are needed to sustain project progress.<\/p>

  While efficient, placements to sophisticated investors mean existing retail shareholders do not have the opportunity to participate under the same terms. The announcement does not mention any plans for a Share Purchase Plan or other retail offers, nor indicate if such options are being considered.<\/p>

  Secondary Trading Notice Under Section 708A of the Corporations Act 2001<\/h2>

  Alongside the placement completion, Audalia issued a secondary trading notice pursuant to Section 708A(5)(e) of the Corporations Act 2001. This standard legal notice permits the on-sale of shares issued without full disclosure by confirming that exemption conditions have been satisfied.<\/p>

  The notice confirms that shares were issued without disclosure under Part 6D.2, that the company complies with Chapter 2M and sections 674 and 674A of the Act as of the notice date, and that no excluded continuous disclosure information exists that investors or their advisers would reasonably require to assess the company’s financial position or share rights. These confirmations allow the shares to be freely traded on-market without further disclosure.<\/p>

  Audalia’s Funding Strategy as It Pursues Project Milestones<\/h2>

  The company’s statement that it "continues to assess all funding alternatives" signals board awareness that the $450,000 raised may not cover all capital needs for the Medcalf project. Resource development typically requires staged funding aligned with phases of approvals, studies, and construction.<\/p>

  Investors should watch for announcements regarding new placements, strategic partnerships, debt financing, or other funding avenues. The company did not provide guidance on total capital requirements in this announcement, leaving future funding scale uncertain based on current public information.<\/p>

  Company Background and Contact Information<\/h2>

  Audalia Resources Limited is an ASX-listed resource company focused on developing the Medcalf project. CEO and Executive Director Brent Butler is the authorised contact for the update and can be reached via the company’s Perth office, reflecting its Western Australian operations. More information is available at www.audalia.com.au.<\/p>

  The announcement was authorized by Audalia’s Board of Directors, confirming full board approval of the placement completion and secondary trading notice. Board involvement is standard for material capital raises and highlights the significance of this funding event for the company’s near-term plans.<\/p>

  Share Price Context and Market Impact<\/h2>

  The placement price of $0.03 per share provides a valuation reference at the time of the transaction. Placement prices often include a discount to market prices to encourage investor participation, although the announcement does not specify how this price compares to recent trading levels.<\/p>

  The immediate impact on Audalia’s share price was not available at the time of writing. The issuance of 15 million new shares will increase the total share count and dilute existing shareholders proportionally. The updated total shares on issue were not disclosed in the announcement body but can be found in the separately lodged Appendix 2A.<\/p>

  Upcoming Developments for Audalia Investors to Monitor<\/h2>

  Investors should look for updates on regulatory approvals and permits for the Medcalf project, as these remain critical to advancing development. Announcements confirming receipt of key approvals would mark significant progress.<\/p>

  Additionally, investors should watch for any further capital raising activities as the company advances the Medcalf project. The mention of ongoing assessment of "all funding alternatives" suggests that additional funding rounds may be forthcoming. Market participants will also closely follow any strategic partnerships, offtake agreements, or investor announcements that could signal the project’s commercial viability and Audalia’s capacity to fund its development goals.<\/p>